TD001

DRUG2 trials

Sponsors

T.O.A.D. Oncology S.A., T.O.A.D. Oncology SA

Conditions

Metastatic Castration-Resistant Prostatic CancerMetastatic castration-resistant prostate cancer

Phase 1

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

RecruitingNCT07258407

T.O.A.D. Oncology SAMetastatic Castration-Resistant Prostatic Cancer

Start: 2026-01-30End: 2029-03-01Target: 180Updated: 2026-05-29

A Phase 1/2 dose escalation trial with administration schedule exploration evaluating single agent TD001, a PSMA-targeted antibody-drug conjugate, in patients with PSMA-expressing metastatic castration-resistant prostate cancer

Not yet recruitingCTIS2025-523273-41-00

T.O.A.D. Oncology S.A.Metastatic castration-resistant prostate cancer

Target: 110Updated: 2026-01-21